Dimpy Mehra, PharmD

Bristol Myers Squibb

Poster(s):

• P0969 - Sustained Efficacy and Safety After 5 Years of Continuous Ozanimod Treatment Independent of Clinical Remission Status: An Interim Analysis of the True North Open-Label Extension Study
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET

• P0970 - Impact of Baseline Albumin Levels on Ozanimod Efficacy: A Post Hoc Analysis of the Phase 3 True North Study
  Sunday, October 27, 2024

  3:30 PM – 7:00 PM ET